Angiogenesis in goitrogenesis

Current Opinion in Endocrinology and Diabetes

Volumn 10, Issue 5, 2003, Pages 341-346

  Eggo, Margaret C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; CYCLIC AMP; FIBROBLAST GROWTH FACTOR; PROTEINASE; THROMBOSPONDIN; THYROTROPIN RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; CELL FUNCTION; ENDOTHELIUM; GOITER; REVIEW; THYROID FOLLICLE CELL;

EID: 32744454882     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200310000-00007     Document Type: Review

References (57)

1. Tunbridge WM, Evered DC, Hall R, et al.: The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 1977, 7:481-493.
2. Derwahl M, Studer H: Multinodular goitre: much more to it than simply iodine deficiency. Baillieres Best Pract Res Clin Endocrinol Metab 2000, 14:577-600.
3. Fagin JA: Minireview: jiranded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 2002, 16:903-911.
4. Velazquez OC, Snyder R, Liu Z, et al.: Fibroblast-dependent differentiation of human microvascular endothelial cells in to capillary-like 3D networks. FASEB J 2002, 16:1316-1318. This study describes the re-creation in vitro of vascular networks.
5. Kriehuber E, Breiteneder-Geleff S, Groeger M, et al.: Isolation and characterisation of dermal lymphatic and blood endothelial cells reveal stable and functionally specialised cell lineages. J Exp Med 2001, 6:797-808.
6. Chang L, Kaipainen A, Folkman J: Lymphangiogenesis new mechanisms. Ann N Y Acad Sci 2002, 979:111-119.
7. Stevens T, Rosenberg R, Aird W, et al.: NHLBI workshop report: endothelial cell phenotypes in heart, lung and blood diseases. Am J Physiol Cell Physiol. 2001, 281:C1422-C1433.
8. Tscheuschilsuren G, Aust G, Nieber K, et al.: Microvascular endothelial cells differ in basal and hypoxia-regulated expression of angiogenic factors and their receptors. Microvasc Res 2002, 63:243-251. This study elaborates the differences in the regulation of angiogenic factor production by microvascular endothelial cells.
9. LeCouter J, Ferrara N: EG-VEGF and the concept of tissue-specific angiogenic growth factors. Cell Devel Biol. 2002, 13:3-8. This is an excellent, comprehensive review of differences in endothelium from different sites and the effects of EG-VEGF.
10. LeCouter J, Lin R, Tejada M, et al.: The endocrine-gland derived VEGF homologue Bv8 promotes angiogenesis in the testis: localisation of Bv8 receptors to endothelial cells. PNAS 2003, 100:2685-2690. This study gives some information on the receptors for EG-VEGF and Bv8.
11. Papetti M, Herman IM: Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2002, 282:C947-C970. This comprehensive review of the evolution of the tumor vasculature has helpful diagrams and many references.
12. Bussolati B, Deambrosis I, Russo S et al. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J. 2003, 10.1096/fj.020557fje. This formidable account of the characteristics of endothelial cell lines derived from many renal carcinomas describes how they differ from "normal" endothelial cells. The use of CD 105 to select these cell lines may have allowed a broader range of endothelial cell types to be isolated. Insight is provided into the profound differences in endothelial cells and the means by which tumor-derived endothelial cells have enhanced survival.
13. Rissanen TT, Markkanen JE, Gruchala M, et al.: VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003, 92:1098-1106.
14. Patel VA, Logan A, Watkinson JC, et al.: Isolation and characterization of human thyroid endothelial cells. Am J Physiol Endocrinol Metab 2003, 284:E168-E176. This study describes a new tool for thyroidologists.
15. Wollman S, Herveg J, Zeligs J, et al.: Blood capillary enlargement during the development of thyroid hyperplasia in the rat. Endocrinology 1978, 103:2306-2312.
16. Bidey SH, Hill D, Eggo MC: Growth factors and goitrogenesis. J Endocrinol 1999, 160:321-332.
17. Cocks HC, Thompson S, Turner FE, et al.: Role and regulation of the fibroblast growth factor axis in human thyroid follicular cells. Am J Physiol Endocrinol Metab 2003, May:13. epub
18. Gerard AC, Denef JF, Many MC, et al.: Relationships between cell division, expression of growth factors and microcirculation in the thyroids of Tg-A2aR transgenic mice and patients with Graves' disease. J Endocrinol 2003, 177:269-77. This original work describes the microvasculature in thyroid tissue.
19. Bagnato A, Spinella F: Emerging role of endothelin-1 in tumor angiogenesis. TEM. 2002, 14:44-50.
20. Goth MI, Hubina E, Raptis S, et al.: Physiological and pathological angiogenesis in the endocrine system. Microsc Res Tech 2003, 60:98-106. This good review includes coverage of endocrine therapies to limit angiogenesis.
21. Sato K, Yamazaki K, Shizume K, et al.: Stimulation by TSH and Graves' immunoglobulin G of VEGF mRNA expression in human follicles in vitro and fit mRNA expression in the rat thyroid. J Clin Invest 1995, 96:1295-1302.
22. Viglietto G, Ramano A, Manzo G, et al.: Upregulation of the angiogenic factor PIGF, VEGF and their receptors by TSH in cultured thyrocytes and in the thyroid of thiouracil-fed rats, suggest a TSH-dependent paracrine mechanism for goiter hypervascularisation. Oncogene 1997, 15:2687-2698.
23. Bunone G, Vigneri P, Mariani L, et al.: Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999, 155:1967-1976.
24. Scarpino S, D'Aleno FC, Di Napoli et al.: Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor in promoting tumour angiogenesis. J Pathol 2003, 199:243-250. This study shows that Met is increased in papillary thyroid cancer and that Met activation increases VEGF, thus showing a route separate from TSH receptor activation to elevate VEGF.
25. Wang JF, Milosveki M, Schramek C, et al.: Presence of possible role of vascular endothelial growth factor in thyroid growth and function. J Endocrinol 1998, 157:5-12.
26. Ali Behzaian MA, Windsor LJ, Ghaly N, et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J. 2003, 10.1096/fj.02-0484fje This articles addresses the mechanism of the permeability changes induced by VEGF, which involves beta catenin signaling and uPA.
27. Ramsden JD, Cocks HC, Shams M, et al.: Tie-2 is expressed on thyroid follicular cells, is increased in goiter, and is regulated by thyrotropin through cyclic adenosine 3′,5′-monophosphate. J Clin Endocrinol Metab 2001, 86:2709-2716.
28. Kim I, Kwak HJ, Ahn Je, et al.: Molecular cloning and characterisation of a novel angiopoietin family protein angiopoietin-3. FEBS Lett 1999, 443:353-356.
29. Koh GY, Kim I, Kwak HJ, et al.: Biomedical significance of endothelial cell specific growth factor, angiopoietin. Exp Mol Med 2002, 34:1-11. This lucid, fascinating paper reveals much of the biochemistry of the angiopoietins.
30. Davis S, Papadopoulos N, Aldrich TH et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerisation and superclustering. Nature structural biology: 2003, 10:38-44, 146. This state-of-the-art paper suggests the enormous complexity of the interaction of Tie-2 receptor with the angiopoietins. Despite the antagonistic functions of Ang1 and 2, their modular structure and multimerization state are similar, suggesting a difference in their receptor-binding domains.
31. Ye F, Florian M, Magder SA, et al.: Regulation of angiopoietin and Tie-2 receptor expression in non-reproductive tissues by estrogen. Steroids 2002, 67:305-310.
32. Wang X, Zheng W, Chirstensen LP, et al.: DITPA stimulates bFGF, VEGF, angiopoietin and Tie-2 and facilitates coronary arteriolar growth. Am J Physiol Heart Circ Physiol 2003, 284:H613-H618. Thyroid hormone analogue which was shown to change expression of angiogenic molecules.
33. Babaei S, Teichert-Kuliszewska K, Zhang Q, et al.: Angiogenic action of angiopoietin-1 requires endothelium-derived nitric oxide. Am J Pathol 2003, 162:1927-1936. This study demonstrates the crosstalk between signaling pathways and shows a direct link of PI3-K with nitric oxide.
34. Jones N, Iljin K, Dumont DJ, et al.: Tie receptors: new modulators of angiogenic and lymphangiogenic responses: nature reviews. Molec Cell Biol. 2001, 2:257-267.
35. Valenzuela DM, Griffiths JA, Rojas J, et al.: Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci 1999, 95:1904-1909.
36. Hughes DP, Marron MB, Brindle NPJ: Antiinflammatory endothelial cell tyrosine kinase Tie-2 interacts with a novel nuclear factor kB inhibitor, ABIN-2. Circulation Res. 2003, 92:630-636. This highly original paper from this group is of particular interest to thyroidologists because the anti-inflammatory role of Tie-2 is explored.
37. Xu Y, Yu Q: Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. J Biol Chem 2001, 276:34990-34998.
38. Carlson TR, Feng Y, Maisonpierre PC, et al.: Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 2001, 276:26516-26525.
39. Fiedler U, Krissl T, Koidl S, et al.: Angiopoetin-1 and -2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the EGF-like repeats. J Biol Chem 2003, 278:1721-1727. This study identifies the regions of Tie-2 necessary for binding Ang-1 and -2.
40. Mitsutake N, Namba H, Takahara K, et al.: Tie-2 and Ang-1 expression in human thyroid tumors. Thyroid 2002, 12:95-99.
41. Klein I, Ojamaa K: Thyroid hormone and the cardiovascular system. N Engl J Med. 2001, 344:501-509.
42. Hudlicka O: Is physiological angiogenesis in skeletal muscle regulated by changes in microcirculation? Micorcirculation 1998, 5:5-23.
43. Rivillis I, Milkiewicz M, Boyd P, et al.: Differential involvement of MMP-2 and VEGF during muscle stretch versus shear stress-induced angiogenesis. Am J Physiol Heart Circ Physiol. 2002, 283:H1430-H1438.
44. Tanaka K, Sonoo H, Kurebayashi J, et al.: Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma. Clin Cancer Res 2002, 8:1125-1131.
45. Lafleur MA, Handsley MM, Knauper V, et al.: Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type matrix metalloproteinases (MT-MMPs). J Cell Sci 2002, 115:3427-3438. This thorough paper delineates the role of matrix metalloproteinases (particularly MT1-MMP) in tube formation and concludes that inhibitors of these enzymes may be useful clinically to inhibit angiogenesis.
46. Ramsden JD, Yarram S, Mathews E, et al.: Thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen. J Endocrinol 2002, 173:475-481.
47. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 6(Suppl 16):15-18.
48. Ye C, Feng C, Wang S, et al.: Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology 2002, 143:3522-3528.
49. Ogawa T, Takayama K, Takakura N, et al.: Anti tumor therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 2002, 9:633-640.
50. Panigrahy D, Singer S, Shen LQ, et al.: PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002, 110:923-932. This exciting paper is of great interest to thyroidologists because thiazolidinediones could be used to inhibit thyroidal angiogenesis as well as follicular cell growth.
51. Nikiforova MN, Lynch RA, Biddinger PW, et al.: RAS point mutation and PAX8-PPAR-gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88:2318-2126. This useful study confirms, with a good database, the incidence of PAX8-PPAR gamma rearrangements shown in earlier work.
52. Martelli ML, Iuliano R, Le Pera I, et al.: Inhibitory effects of PPAR gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002, 87:4728-4735.
53. Ohta K, Eno T, Haraqguchi K, et al.: Ligand for PPAR gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86:2170-2177.
54. Tuttle RM, Fleischer M, Francis GL, et al.: Serum VEGF levels are increased in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol. 2002, 87:1737-1742.
55. Iitaka M, Miura S, Yamanaka K, et al.: Increased VEGF levels and intrahyoidal vascular area in patients with Graves' disease. J Clin Endocrinol Metab 1998, 83:3908-3912.
56. Fannon M, Williams KF, Dow CJ, et al.: Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment. FASEB J 2003, 17:902-904. Possible anti-angiogenic therapy is indicated.
57. Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003, 273:83-101 This is an exciting review of a rapidly growing area, neglected here because of space constraints.